Commentary

Video

Dr Langer on the Evolution of Adjuvant Immunotherapy in NSCLC

Corey J. Langer, MD, discusses how the use of adjuvant immunotherapy has affected the resectable NSCLC treatment paradigm.

Corey J. Langer, MD, director, Thoracic Oncology, Penn Medicine; and professor, medicine (hematology-oncology), the Hospital of the University of Pennsylvania, Perelman School of Medicine, discusses how the use of adjuvant immunotherapy has affected the resectable non–small cell lung cancer (NSCLC) treatment paradigm, as well as unanswered questions in this arena.

Related Videos
Kathleen N. Moore, MD, MS
Rona Yaeger, MD
 PER® International Symposium on Melanoma and Other Cutaneous Malignancies
Robert
Charles B. Nguyen, MD
YI LIN, MD, PHD
Dr Fakih on the FDA Approval of Sotorasib Plus Panitumumab for KRAS G12C–Mutated mCRC
Al Malki
Ian Krop MD, PhD
Timothy S. Fenske, MD, MS